2482 related articles for article (PubMed ID: 19653230)
21. High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells.
Mozar A; Haren N; Chasseraud M; Louvet L; Mazière C; Wattel A; Mentaverri R; Morlière P; Kamel S; Brazier M; Mazière JC; Massy ZA
J Cell Physiol; 2008 Apr; 215(1):47-54. PubMed ID: 17894387
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
23. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption.
Park CK; Kim HJ; Kwak HB; Lee TH; Bang MH; Kim CM; Lee Y; Chung DK; Baek NI; Kim J; Lee ZH; Kim HH
Int Immunopharmacol; 2007 Dec; 7(12):1507-16. PubMed ID: 17920527
[TBL] [Abstract][Full Text] [Related]
25. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
[TBL] [Abstract][Full Text] [Related]
26. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
28. Rhinacanthin C Inhibits Osteoclast Differentiation and Bone Resorption: Roles of TRAF6/TAK1/MAPKs/NF-κB/NFATc1 Signaling.
Tomomura M; Suzuki R; Shirataki Y; Sakagami H; Tamura N; Tomomura A
PLoS One; 2015; 10(6):e0130174. PubMed ID: 26083531
[TBL] [Abstract][Full Text] [Related]
29. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.
Kimachi K; Kajiya H; Nakayama S; Ikebe T; Okabe K
Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):297-308. PubMed ID: 21225243
[TBL] [Abstract][Full Text] [Related]
30. Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling.
Mazière C; Louvet L; Gomila C; Kamel S; Massy Z; Mazière JC
J Cell Physiol; 2009 Dec; 221(3):572-8. PubMed ID: 19725047
[TBL] [Abstract][Full Text] [Related]
31. Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis.
Cheng CP; Sheu MJ; Sytwu HK; Chang DM
Rheumatology (Oxford); 2013 Apr; 52(4):609-22. PubMed ID: 23221330
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effects of obovatol on osteoclast differentiation and bone resorption.
Kim HJ; Hong JM; Yoon HJ; Kwon BM; Choi JY; Lee IK; Kim SY
Eur J Pharmacol; 2014 Jan; 723():473-80. PubMed ID: 24334279
[TBL] [Abstract][Full Text] [Related]
33. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
[TBL] [Abstract][Full Text] [Related]
34. Piperine alleviates osteoclast formation through the p38/c-Fos/NFATc1 signaling axis.
Deepak V; Kruger MC; Joubert A; Coetzee M
Biofactors; 2015; 41(6):403-13. PubMed ID: 26627060
[TBL] [Abstract][Full Text] [Related]
35. Calcitonin inhibits osteoclast formation in mouse haematopoetic cells independently of transcriptional regulation by receptor activator of NF-{kappa}B and c-Fms.
Granholm S; Lundberg P; Lerner UH
J Endocrinol; 2007 Dec; 195(3):415-27. PubMed ID: 18000304
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo.
Franco GC; Kajiya M; Nakanishi T; Ohta K; Rosalen PL; Groppo FC; Ernst CW; Boyesen JL; Bartlett JD; Stashenko P; Taubman MA; Kawai T
Exp Cell Res; 2011 Jun; 317(10):1454-64. PubMed ID: 21420951
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory effect of cantharidin on osteoclast differentiation and bone resorption.
Kim MH; Shim KS; Kim SH
Arch Pharm Res; 2010 Mar; 33(3):457-62. PubMed ID: 20361312
[TBL] [Abstract][Full Text] [Related]
39. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling.
Rahman MM; Bhattacharya A; Fernandes G
J Lipid Res; 2006 Aug; 47(8):1739-48. PubMed ID: 16702601
[TBL] [Abstract][Full Text] [Related]
40. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH
Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
